INMB - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the INmune Bio First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. is to it Mr. time, this my introduce pleasure At Bio. CFO David and INmune Moss, Co-Founder of David, yours. floor the is

David Moss

Thank you, INmune Paul, the Co-Founder you XXXX for of and results. call good afternoon, us financial Tesi, the everybody. is for INmune Dr. call CEO me Bio, for With Bio's RJ our quarter joining first in who on We and DN-TNF CJ Barnum, Dr. disease will a will about Phase in who speak and X provide programs business treatment-resistant platform; update Phase both our and depression. of of Alzheimer's on Neuroscience, X our program Head thank

specific any INmune reflect circumstances. disclaims underlying statements to may forward-looking events Bio or on of Before Please and Reform the to made SEC. results risk actual most recent such I the change. differ forward-looking everyone as Act only by including safe factors these filings, and assurance made risks required These the the release, involve are circumstances Private date see not can There's placed reliance forward-looking harbor statements are on Undue our no company's statements, for statements responses forward-looking we the as the of XXXX. and with call uncertainties those begin, by questions cause filing provision that to of information they disclaimer law, of as that historical in well which except Litigation materially the speak management facts should in statements. this earnings Securities as as quarterly update the company's any under be outcome. from remind statements facts, press to forward-looking conference future SEC on of Except statements obligations statements these of forward-looking the statements

our like say and iceberg. pursuing turn state and platforms INKmune I'd I'd we optimistic RJ call start, we progress, INmune potential the the to indications. have XPro is NK of to our Bio. RJ? Both Co-Founder platforms, cells from like you two today about for we're developments Dr. CNS what just significant tip to the are Tesi, on the like of CEO to that very on To to and update that Now, over

RJ Tesi

David, you, call. and thank joining for Thank the you, everyone,

are CJ will the updates first of treatment As then usual, will cell on will the clinical with death a we CNS the have neuroinflammation with A-D-i, based I AD ADi. about INmune beyond connections is David are move Bio opportunities on biomarkers key procognitive diseases remarks XPro and upcoming the XPro. Phase we believes hand derisk reviewing from the of and target with VP successful highlight the Alzheimer's new is arrange select that neuroinflammation synaptic of for design are help with of what Development, beyond diseases. will obviously, be period, We X Phase nerve the neurodegenerative by XPro in effect of biomarkers learned prevention to recently to treating to first the we my X ADi of The and decline programs. opportunities I and are the the provide Phase the restoration CNS Alzheimer's programs. platform the patient for treatment cause of XPro the and real. programs, programs before financial and ADi the will that milestones trial to trials therapy And provides disease. on new of cognitive a ADi announced results of of relevant the dosing X These in patients Q&A. will trial. the define in use ADi, term our to of Alzheimer's The that's endpoints the programs disease with Dr. patient for as developments trials the and our use we Barnum, it in finish start staging duration The in to takeaways our dose, speak subsequent quarter XPro the to detail. I first over those and of disease.

programs and diseases more Foundation, We More covering than preclinical announced Neuroinflammation call respectively. patients performing or a funding resistant the X indications. extramural These on ALS. website. from a our of studies a have CNS of something NIH in the opportunities ALS began are before in – Phase we the treatment the program found hint program publications non-dilutive of Association, IND-enabling and depressed us. dozen neuroinflammation, gives Each TRD, TRDi, depression, than these publications in these can Alzheimer's with XX is common the denominator be with

be will in coming trial. ADi mild patients We Phase X enrolling in the additional months the

additional trial initiating X Phase Conference be what will quarter, AD/PD data We presented trial But successful our first, MCI at first the Phase we soon. during in XXXX Barcelona. from the X the

Bio to ability disease disease. the development disease, key versus Our of conversion development to in step Alzheimer's a Imeka, may to prove and There identify MCI disease. simple. AD our an provide Alzheimer's in also Development database. for a not data expand trial detailed clinical get the of into moving safety from the These trials. ADi, our adding Alzheimer's XPro future, answer only do measures we to that trials at will relevant commercially means ample partner, implications preventing and MCI but different MCI imaging mild now? market of progression dementia In our two and INmune programs provide insight and matter information By an clinically for relevant Alzheimer's CJ of of from toward may VP have Why and MCI of these patients are program. help our pathology the of Alzheimer's we to on be The start is efficacy patients a at closer our approval, separate will disease us clinical demonstrated day-to-day. to data Both drove trial, drug and MCI related the AD, clinically more MCI beyond mild elements in achieve trials goal white necessary safety of CJ? to decision registration ADi. risk the architect quite Barnum, the CNS are predicting trials

CJ Barnum

and MCI asked why Thank is are MCI be Bio three patients second in will conducting treat studies. primary in mild and cognitive do will we preclinical we ADI: genetic a you, currently get why questions The trials want dementia. The we enrolling nontraditional doing Simply First, and neuroinflammation causes to use I this separate on AD, Phase by overwhelmingly most our why use RJ. are Why INmune later one bullish short? of are: AD? X evidence trials this small for speaking, to ADi. in are two And XPro epidemiological and summer. begin we that supported in the with that endpoints? enrolling; trials common mild reiterate is

TNF inflammatory the is the and for believe most the inflammatory TNF, of we activity development factor In neuroinflammation of of master XPro, modulates regulator AD. driving Soluble the short, target every AD. important target is nearly in

of drives preserves drug transmembrane may a drug that because that for of repair, necessary TNF. dementia, procognitive neuronal it have TNF CNS trans-membrane part neutralizes we be precisely that preserves that the the mediated importantly, soluble TNF is species We TNF, repair. and More the believe

for get by has this different mild I been the our we But are far, mentioned separate because biomarkers doing hypothesis biomarkers By them early how of individual and to earlier. a we and trials back – will So nonclinical for separating the AD each our into are picture studies. supported studies, changing. clinical What questions are clearer MCI disease.

it ADi being that patients advantages, faster not widely this allows trial and with reliably. powered and rapidly progression reality more patients. wanted shorter Second, patients to This increased inflammation with known the for prominent smaller trials. most emphasize design with and progress adequately consistent I clinical between is because progress

Finally, MCI. scales occurred that measure we changes have mild chosen and that AD during cognitive

cognition, patients, occur require placebo-controlled and studied of the biology measurements if EMACC, on proof for scale. and and Patients goal, study This inform and can in that therefore, cognitive will patients. that To a MCI rate in determine and early found study the measure ADAS-cog is of moderate MCI mild must empirically in be can The decreases are This changes is study slow probability plagued to will a neurodegeneration drug cognitive and MCI about using be different on this is AD months. or and of they three by and AD reach a of was the the scale. patients receive will trial. America. Australia of moderate extensive the trial XX are The use studied early we of strategy XPro XPro Specific registration low primary XPro in severe change of separately. clinical developed from AD conversion different will in that severe MCI effect Why derisk cognitive biological dictate patients derived AD. diverse randomized, enroll the registration study inflammation, The occur important? two-to-one, of help was primary be these rate is design frequent biomarkers function. changes capture and The blinded, in Our trial we to will EMACC cognitive biomarker study where due to in MCI AD. North that changes success. decline placebo, increases that disease, endpoints, goal and this be to randomized information this together AD The are whereas us package those to studies cognition a clinicaltrials.gov. and of with and to risk

This effect XXX proof-of-concept X of is cognition. a key blinded the powered will patients Phase study randomized, secondary on six mild with to endpoints in months show significant patients AD ADi. study primary placebo-controlled enroll and Our

Alzheimer's MCI are clinical that measure for As patients in disease. the cognitive that described the above changes mild using and trial, occur with endpoints we

a We are designed path will and confident study. succeed we clear a study for registration have that provide a

have is both feature additional patients an the pace that up XPro months. mentioned treating be started MCI above, three-month timelines. the once to patients complete respectively, patients XX are mild offered trials, and our for RJ As six and will meet we trial on and all AD A to of

safety database. additional XPro fact all feature of we on attractive for patients that short believe be will be time, efficacy During the patients. We and the to an clinical data timeline that our the and able will trials on add will will to go safety recruiting obtain and

inflammation. resistant of have Now, Approximately those turn the will treatment of patients believe of demonstrated a patients X with approximately TNF biomarkers treatment nonselective benefit third I with we to with are a in Proof-of-concept year studies resistant have million that resistance. their for inhibitors biomarkers U.S. will treatment patients per therapeutic is depression neuroinflammation depression. treatment cause resistant There of depression. a and

of pathway and We supported impact reward depression Phase have the Consistent strategy, of will including of treatment will of patients National motivation, on endpoints. Institute brain. and traditional with secondary be of endpoint blinded alongside million select MRI announced study trial anhedonia grant and XPro of is scales functional biomarkers the depression the patients a placebo-controlled symptoms, we key patients inflammation. six-week our resistant inflammation. assessed with XX $X.X study inflammation in assess in is depressive change part X the will of Health. associated This The primary in a a a AD resistant well-documented with in the treatment as biomarkers with The metric which functional XPro key activity XPro with from development by

study strategy As pathology a with disease mechanism patients available of the ADi, of the the be information and as XPro. start with this we target will TRD with about More get for to closer the engagement enrichment aligns neuroinflammation date.

me to discuss pass INKmune. the RJ platform, let back call our second to Now, RJ?

RJ Tesi

alone platform cytokines, manner INKmune are expensive our cocktail. the Cytokines these process. problems an INKmune NK of when elegant that do an can to product a by as the a These a in processing. All that killer converting their in or cumbersome a population. toxicities NK circulation, to therapy the vivo a management or have CJ. memory-like problem. therapy. as natural either Cytokines use the cells in requires patient's toxicities complicate is as of and classify other need INKmune body, prime safe solves complex cytokines when are They you, while cytokine. a for into without support, call we proprietary and directly they're added NK patient killing or their their companies is own sick part ex cancer cells manufacturing expand phenotype INKmune engineering own and Why priming the genetic simple. culturing cytokine? into cell effective Thank we their primary given NK to multi-cytokine patient

seen expanded MDS/AML. include we NK into have expect COVID, patients Like the to recruit in clinical This differentiate cell two inability our solve of our Even their the in AML three will INKmune this of of we therapy INKmune MDS strategies. in to barrier hospital the addition approach AML for other to patients, frustrated therapy MDS To trial are the in must to come we with treatment. enrollment. We have from problem, effectiveness INKmune And you, this patients era program the to patients the eliminates one in trial. patients.

of feet is malignancies? that NK The oxygen little obtain these do hematologic INKmune a NK-targeted well And NK to a additional very is NK-directed short Colorado. from up perform XX% the patient that TME you tumor not solid Mark quite makes level go without skiing tumors. oxygen lower Think cancers working in abnormally magic commercial cells their a arrive, solid are more discovered low Why XX% working hypoxic it tumors. focus microenvironment us year. is in that We about level on Hypoxia inhospitable therapies to changes sea you of you than therapies to microenvironment? walk we at in than believe are breath. function. level. EU. cell It on work don't flight cell X,XXX work normally. Lowdell is simple. why tumor is actually first What NK this tumors, That cell is open hypoxic sense at focus therapies of and when allow biology. where stairs The in second getting it's prevents since and has data solid site a immunosuppressive. most must can't The When two will based is

cells. you, is with compared is by killing unmatched cancer. More in the this Because a times the solve this INKmune. produced is market. cancer measure suited San certainly killing, surrounded NK cells cell kill work. Killer least days cannot by a of after to it tumors. tumors, don't ideally kill INKmune-primed second The than the that INKmune by protect that's our much by upregulating it. higher the the larger were that any this the cells persistence of prolonged proteins how NGKDX+ presented the and present XXX problem microphages, in INKmune treating cytokine oxygen INKmune-primed memory-like NK a the is immunosuppressive to Diego, hypoxic it effective cells To patients kill nutrient This solid NK INKmune trying good Lowdell environment feel kill TME just cells Like blood these compared a NK T when cells. treatment of liquid cannot last for and a and the regulatory is cancer that when To a responded marrow Professor for Innate at company killing. INKmune cancer survive cell many pivoting cancer cancer NK are NK that – You at NK to NK cells. and thrive, on receptors cytokines. tumor controlling INKmune, hypoxic, cells cell. and dose of cells survival higher solid cells the that of mitochondrial knowledge, are for kill cells is we again. produces all and produces cells, NK chaired cell is TME. in cytokine-primed avidity memory-like market single normoxia. a immunosuppressive probably every our than avidity survive, their last is use normal Conference therapeutic Avidity session NK overcome in to why levels to thrive is of NK cells in NK tumors. are problem appears is kill MDSC and the the month cancer. tumor-activated and bone In INKmune NK assays in priming of in INKmune in more he at that advantages, memory-like knowledge, is cytokine-primed NK where that toward solid causes cancer

abandoning the is teams, the for company clinical MDS/AML not and source regulatory It the an insight of program. are important We authorities. information and

from We forward will move take what in we are to solid MDS/AML learning tumors.

You already nasopharyngeal know and cell about and ovarian, in renal preclinical the this cancers, stages preclinical but both just beginning. is

David it this turn Moss, I'd to CFO, Solid point, future tumors At of review our over to are items. to certain the INKmune. financial like

David Moss

the our compared the the quarter milestones XXXX. XXXX, and head comparable common the XXXX, million XXXX, for Research for Thank approximately cash XXXX. quarter comparable million loss in approximately upcoming period the for and development expenses for expense and had approximately quarter million ended million to the I'd $X.X XXXX, Q&A. comparable point out or approximately March quarter just the with cash, stockholders ended of to approximately quarter, to period March comparable was includes for Net compared for compared comparable million period that totaled directors brief XX, you, Based approximately XX, on $XX.X XXXX, and equivalents – and a mainly we as approximately X million with cash March XX, operating the March shares in March for compared into Revenues was $X.X $X.X with quarter results cash provide was the RJ. Mark we approximately the attributable Other March XXXX. totaled officers $XXX,XXX we $X.X to General ended before At believe XXXX. for our approximately current the XXXX. of filed in $X.X $X $X.X for in XX, expenses the million like in XX, is for overview million million current X-K period fund during compared to our million. an the operations XXXX, with our XX, $X.X sufficient SEC, plan, ended XX,XXX administrative XXXX. I'll financial the director. period to myself ended in $X.X That on and Lowdell, for cash. late previously RJ, to reported one in company sold

X, stock had of million May the shares company of common XXXX, approximately outstanding. XX.X As

Now, on and list I Q&A. catalysts upcoming our move would to milestones and like before

Phase cause our our first RJ, as by highlighted dosed of Alzheimer's disease. of X both a we previously As neuroinflammation in treatment for CJ XProXXXX patient trial and

continue over patients. cognitive we plan patients with we months six-month coming first a for Phase In X trial of initiate anticipate to XPro months, million $X.X the a three-month depression. enrollment first mid-XXXX. XXX Barring expected line expect half in sometime to in enrolling grant by to half XXXX, partially program funded to of to coming unexpected we the results treatment mild We is line plan delays, – order a our In reach any for the impairment. target grant. patients XXXX. Phase This late the initiate resistant results top X having program of Top NIH in XX-patient

high-risk data in We patient expect MDS/AML INKmune further open-label to program as enroll. the continues

to in or in we tumor another this launch ovarian XXXX. year Finally, in plan cancer study INKmune second a solid

time advance questions. I'd it potentially Paul? thank and the pleased back creating we're like to to quarter poll to I'd and our milestones. evaluate Paul summary, toward At you to and continue point, progress with So for for we your to attention, turn this for our pipeline as like

Operator

you. Thank

a conducting [Operator Instructions] be session. now will you. Thank question-and-answer We

Please Our Mamtani your Riley question. first Securities. with with Mayank question from B. is proceed

William Wood

update making. on questions. been really Mayank William today. on of got progress This and congratulations you you've couple the Wood a the I've really for is I that all Hi. appreciate provided Mamtani that

MCI The first, AD on mild trials. and of kind your focused

difference with my eyes, potentially and the mild an and/or the populations a three two going in the severe population about see MCI bigger. of slightly trial trial is I the limits guess, is population could readouts you timeline? and Maybe and longer for the should curious just the So in and months, the it's for EMACC, more six severe these the in running trials difference less months. how be – thinking the you and earlier and is

your Just curious about that. thoughts on

RJ Tesi

to Yes. answer going Thanks, William, I'm CJ let that.

CJ Barnum

of I long really So to but it's it. question, a there's It's a mean, answer. good elements lot a

a different to we MCI as resources into before I back as to think disease, that make that time in in the what lot need it. referring ways, looking the and we two our we if view these, biomarkers said different we're right spot some sure is call, And diseases. understand of put we work viewed a in we

The other to involved the expect. length is has you studies in with what factor these do of that

expectation, example is for how if be. to the that of So to trials dictates slow by your need the disease decline long XX%,

biomarkers different patients. stop understand expect to if the working – patients between are is and a rate actually study you drug need proof-of-concept. If as the is our to different our obviously in because more the And we the MCI we to move And expectations how will we biomarkers But we not need before population reason timeframe. a that. progressing, that's a really, understand do into three-month the that had and MCI reflect truth we well conversion mild

RJ Tesi

Yes.

and of who me depends of she Let architects we one also. what William, it just with our and in before, just spent on of Judy said, couple the mentioned really the I Jaeger, the cognitive reinforces guru we've one points days included CJ made your important that a of And jump team EMACC. the mean, here, expectations.

you more patients. two If populations, you you're declining to time, need expecting between more need differentiate

As times, we've stable. patients flat-line our expecting we are euphemistically said say many – be we to or

– shall expecting the meaningful of for a aren't demonstrating in the That drug. there's way the worse. patients than our to get that patients, chance fact, the we effects MCI a even a really opportunity we'll have say, that. And better we changes in outcome the So in

confident And by back using to us MCI the lack suddenly more completely ADAS-cogs, our of more for comment inappropriate tool of to the for sure. One more of is which again, just CJ. sensitive So once a allows be traditional development. sensitivity goes for AD sure, it mild

CJ Barnum

Yes.

cognition to piece this we've – the to do what's – think address because that able ADAS-cog measure me along, saying believe we just have I measure that's doesn't changing, And be important. you the that. all what's been you sort let of to So and have you

empirically EMACC was why to So the is determined It this derived. that. was do really

Now, the But is isn't problem ADAS-cog the field good. that very this convention understands this a is problem, in knows a business.

you we that know studies secondary based an have CDR. So in to be remember powered our the and is that endpoint – CDR we as The the registration well. endpoints can that studies, can used used on the CDR

believe a even developing a sure a the though EMACC make think to that endpoint all So we be will it have superior our able in we're we are as EMACC the we be pocket use our covering EMACC will in way and CDR bases. we the to – potentially back in we primary registration the will trial, that be

RJ Tesi

a had question? You second

William Wood

have a pushed Actually, been in and is it from your slightly then quick two least quarter. one at Yes. your like, – timelines at general, back least quick looks well, fourth ones. One

how a get feeling interpret this? we to should trying Just on

RJ Tesi

No. We of half That's first what said year and the we'd have the ADi, the exactly of second the half year. we mild plan. the MCI

William Wood

take you patients. AML obviously I I'll started then, And lastly, trial, INKmune Okay. on incorporating your the guess, just that.

would the MLS, be going to forward? to extra enroll treat both? be get appreciated. trying to treating we that on how color be are still Obviously, viewing said feeling trying Any you you you'd trial Just but a be should going both,

RJ Tesi

question. yes, So fair

chemotherapy number bone transplant circulating to I'm have categories, the out. criteria AML candidates AML response blast So with incomplete failed that who blocking Patients to include of patients with criteria inclusion bone and expanded for there's we've that transplant. now other marrow one for marrow a a aren't

into all same are trial the these lumped So now. being

some six remember, It's trials. other no on out And biomarker-driven both more their MDS, trial are there's a I and complete had of patients months these disease is we AML of therapy. that after with high-risk responses last dose on actually control of bad two this which side. pretty So in. the not know, actors a is their INKmune pre-AML, good mean, than you trial with one as

patients So now disease, lives. are because normal they haven't have we still these cured them but living

really, we it I at paragraph, like to what's I look in the So think as happening the it described way MDS/AML. last is in

We reason can't trials chasing enrolling tell anybody on I detail are The heck having that way positively to went NK frustrated too ability in can enrolling is the as enroll And the few companies the because the AML/MDS in such there's I that of patients trials. you we way cell too INKmune who's trouble patients. affect many function we differentiate TMA of companies. tumors to company, should will opportunity tumors, solid a dramatically other we why that every they not has is presented huge knowledge, product. is No my because that's why from now believe solid are us other and we We approaching evidence tumors. for know for future think INKmune the solid attack

trial, interesting trials, plans and we have pudding Now, need to other and open need some that you'll hear that ovarian about. the afoot to is the open we in the proof means we

but than We there tumors, number solid patients future patients. and will the opportunity malignancy that tumor the nine of are publicly do finish there's solid only the times hematologic I here, of I'm MDS/AML believe, saying trial, is it INKmune and

William Wood

the Congratulations color appreciate I again. Excellent. extra there.

Operator

you. Thank

question with next your proceed Global from question. Cross Matthew comes Partners. Alliance Please Our with

Matthew Cross

solid you guys. Good probably I a do the therapies solid actual any of question was, the Hey, allogeneic within in of cells or the and into data or nothing out tumor from NK questions as actually taking here solid way setting. exactly I into case, tumors, delivering of how jump RJ, the is we're accurately other direction certainly regarding all of the where pointed in couple this that afternoon INKmune too space? be guess, you me. moving line had much thanks The for on going. promising in and I tumor guess to I there really cells, patients isn't which NK cells NK that of the yet envision to from think discussion cell kind I'll

the in can other world etc., it, to to approval enhance guess wait avidity Encarta I need at to need to solid solid whichever aggressive sufficiently kind and to the like tumors look and be I in into order more disease guess to can do an of normal, tumors put allogeneic really, that cell it? in and aggressive maybe do go you've that those the of for NK kind way INKmune, cells right need this rejuvenated, INKmune extent, or wait even for is to way, really Or with patients, succinct prove you patient's the you solid another rest agent to solid functioning residual some tumors, types, catch improving get disease? Or the pave NK in can do right described of metrics? to cell to So in these way of experimental the you fight use the you up? suppressed these developer very maybe etc., away tumor field cancer now you

RJ Tesi

reason how They So can I frankly, is, say mean, catch why that meeting cells quite studied understand, they microenvironment. no. really all to hell understand is can on I for the a going there in are going attack what's the about And they're not tumors the I may to function everybody don't clueless they to would solid wait up. their they in be the in of environment are they've think TME. never, set of that because our to but knowledge, if well, tumor in we

Mark is this he NK XX, we not and sauce has Our top-secret, top-secret maybe I but certainly understands our Lowdell. here say, presented, XX years, has and Mark or Lowdell it studying studied been – cells, secret as basically now, really program well. shall

though. bring you a up I think important, that's point

our let certain magic able believe I'll attack, What in don't But we're sensitive are that to and wants of about NK to talking based cancers there's specifically. diseases. about with I careful going programs bulky has a comment bulky the disease. when cancers. him more is for differentiate join so – infiltrates Mark about us cancers, with these he fact we the INKmune criteria the bullet picking on us, call and we patients think, to You're etc., he's be kits, aggressive on biopsies will people only to is

maybe of cancers But choose treat within disease that talked won't burden can allows low a a of certain concurrently and with that battles fact with the I've with way necessarily us – we patients will we other that won't to about. we attack chemotherapy in after types go ideally that will is our the be We that patients immunotherapies. pick –

So stay tuned.

important environment, environment, be that when they NK XX% solid that something because he I'm to throw oxygen the in with other to if blindsided wrong, I'll learn. and Innate immunosuppression. today, everybody immunosuppressive confidence. them admit so us, our has into to hypoxia in the But to has most the work know are no have in be working patient and Conference data and first NK by that others cells cells far, talked was any keep failed is And But gives get making at INKmune and than don't. really that We it. knowledge, NK us why presented we nobody was Killer now supposed in about I cells they thing the think, and that Mark what tumors I

Matthew Cross

No, quickly one super – question. helpful. for think And side to on AD, the switching MCI Understood. I

MCI. of neuroinflammation, maybe to I you're MCI, in contrasting AD guys those quite patients on as patients AD case you're wanted in also in the for the in was looking amyloid But equation. and the at those both looking bit focus will have covered the cases that that think at upcoming equation you TRD and in But have I latter – AD MCI with a particularly around what and two, in TRD study have TRD.

For I need think actually to positive they enroll. to amyloid MCI, be

is that guess, I of like iceberg the indications to case in kind may amyloid? of really you mechanistic potential other the neuroinflammatory by as TRD glial go Parkinson's cell study a can't of enrich or and diseases, places activity on on one could isn't in inflammation how comment that guess activation pretty those should that amyloid, kind well-documented of patients in day you patients, you rationale and filter or since of central normalize other where a something microglial XPro you I trigger So

RJ Tesi

CJ?

CJ Barnum

Yes.

we I think is amyloid don't. differently. question the necessary. I So don't that to answer simple is amyloid view

those us and the to we're believe the that If identify tell for. be have within going select. will brain patients biomarker inflammation we'll biomarker you able inflammation, patients to which we're – that looking patient are to the have And is we the that's going

we previously. patients case to CRP anti-TNF has know been that already respond That high the of blood resistant depression, So published data with of – CRP in levels treatment therapy.

If you a look used at the response. currently are on that TNF inhibitors of treatment as and all the diseases market, is the predictor CRP

for So these think don't next diseases. we I level a need

best to may patients better on time. sure We'll – to I we that have think But need CRP biomarkers. think I that over think focus There biomarker. it's inflammation. that the unravel the we be I just is need make

RJ Tesi

more if I make one could And here. comment

words, In criteria their actionable trial with to to patients other large of Mental National we of the it placebo-controlled pretty the provide with And we thoughtful in was it's trial to blinded depression. will the why when for the win that and NIMH, a are well-designed from they INmune was that know placebo to in One that. be we enough think other – – fact a going this works, for was biomarkers patients. elements And one, CJ is key there's And this biology didn't that Institute one, funding is that: works, of trial Health, trial. future work that information the there know a actually Bio placebo-controlled tranche biomarkers which it diseases. and resistant trial, those going will in how and will applications it key patients do psychiatric it's was designed

Matthew Cross

Absolutely.

the guys. both Understood. for Thanks answers Great, you. Okay. from

Operator

Thank you.

your Our with next question. Please question proceed from comes with BTIG. Tom Shrader

Sung Hong

in calling for is Tom. afternoon. Good This Sung

two have I questions. So

of is AD for question kind MCI. the follow-up and a like First

and exhibit call patients progression. So earlier your you've faster mentioned in elevated more with disease consistent inflammation that

wondering, disease So is progression, follow-up just question at what a a second disease the like clinical faster inflammation? was of have non-elevated stage for write actually. those I that I And the with just separable like

RJ Tesi

CJ?

CJ Barnum

at doesn't progression is between you the of and they've not disease, good part of is the do of whether It's six have they the enormous however important matters patients where biomarker in the to gives inflammation it that the over stage are look you answer the and or The a really got in question. they matter what is course biomarkers of If inflammation. trials. months, faster and or to you months is shorter variance next that it, smaller disease and power low, disease want progresses advantages most XX their the look

Sung Hong

a is, Very the OK. question helpful. Okay. then, so second depression. regarding And

earlier like between the inflammation may to antidepressants bipolar So synergistic response. And and as the that effect? data influences schizophrenia any different the baseline you that established of there indications have other combination But mentioned suggest how a therapy in anti-inflammatory or immune are inflammation role such disorder?

RJ Tesi

So great question.

lot We out with, jury an on example, of whether jury on don't is – advantageous. XPro and combination that. be think still I the a SSRI have a point. any we is don't this out The more will for – still

So have that. the combination most was that onset, patients two patients to documented but think these as what looked have studies looked that not are of have the And don't the question? cohorts that where at at with of answer know schizophrenia, depressed second uniquely I effective, be disease a trauma-related which is really different inflamed, inflammation. may bipolar, the the we

Part of make brain I've brain. levels not mental in has some onset. the the disease patients whether are rewired you highest Those seen schizophrenic gets really the it of inflammation issue In diseases have is is a clear certain developed ever the these circumstances. of once And most a can the are difference where the unique fact, there way.

So soon. be it's will tackling anytime I a not program that

Sung Hong

you. Thank helpful. Very Right.

Operator

Thank you.

Our is with question. with TW Daniel from Please Group. next Research your question proceed Carlson

Daniel Carlson

guys. taking couple a here. Thanks questions. Hi, for my There's

not for one lot out of this. the came getting better of Regarding recently INKmune, a have days And suggested Encarta market was when had much people you're we've with results.

in And is talk – guys bodes well Encarta? if the you also, about wondering you for So what, INKmune program? the what between INKmune I'm results, difference their could just and

RJ Tesi

I'm So thanks, going jump then start let with to answer, that David I'll maybe Dan. and in.

David Moss

number things. So of different a

little six I'll we only think talked intent out in land. They we're it's have as I point that well, NK but an on cell about enrolling early only that a Obviously, few phenotype very patients. big A which the using, think I NK NKGXD+ it is bit that was at is the this cells a market surprised the more. of of part response. cell. Obviously, I they're

do what of do believe date, we're but come data, delivering. companies. as it that help which say I NK seeing to not type doses is to with need is that that patients. the persistence. the need period therapy credit out I – they're with to obviously, long they the of with we of we complications We we gives of cell. get to persistence use. CAR, And to of the the our other that CAR And think a need that that, program, they're use monitoring needed. additional our I credit have us is their of And about over show that jury the time another we're related of we activity get NK would market company cell able with NK hopefully, same more activities get which using – of done a in the similar if the cytokines patients a more to Obviously, a we are what they part they then, get number they've we're feel very to and will think the without cell focused on

RJ Tesi

Yes.

the in case. years is cells be don't Let many, not after – treated, as shall patients in we been very point. here is T-cells free important and lost, they me NK patients soon has disease. relapse. months, make the probably remain, reason is engraftment CAR jump CAR those they a That the patient Patients T-cells That's tend can to that actually work of reason the engraft. that only those and The as many – when work, found engraft. say,

you, persistence, element CAR therapeutic alter how a putting on tumor. an key the cell – can a told I've it's is NK which, So going control your you not something to do already may to for as well

don't have any a major cytokines don't any and toxicity fact, or So the Maybe reason what much the NK manufacturing. of give promote have they cell one. suggests proliferation, close have but We don't I and that they That's give way, it right get – three for to promote to us. to avidity persistence. data haven't is is seen elements. for promote cytokines we NK the giving many is one number is, now, Number we other persistence. patient best-in-class anybody isn't, we're cytokines By not two, promote cells. remember, even the the – this the advantage do And is therapeutic companies

So easy mean, to finally, buckets stuff. the of make. we've I INKmune is got

effective, these cost tolerated. in time it's it's safe simple, NK NK right patient, logistically and memory-like a cell, it's the last of killers. the so, well get kind have long And We They about thrive work tumor we that's make back complicated it because that and immunosuppressive tolerate what cell can solid talked the microenvironment. in earlier, in And will tumors a discussion. hypoxic more I to

Daniel Carlson

it. I got

looking this switching maybe pictures, Just is on gears, with what's CJ, Alzheimer's obviously, but is for recently big Biogen. in at big the talk going

that's going it it you? in you seems sort be just with you can terms talk impact of them going like what's wondering, on and I'm to if for guys But how So positive your about should of recruitment.

RJ Tesi

Biogen start which saga, investment the business Lilly looks feeds have they've like Eisai, obviously, with what's aducanumab. see with people called function stopping right? that new be and that's down more on now news is Let to the they forget But like which an get because and – to every my the – question stepped And not. they're and antibody antibody morning than me in really at look obviously, I anxiously CEO again more I coming their behind up blucanumab, once the

that abandoning anti-amyloid just Biogen wounded ADUHELM it's they duck. the just a So severely not the is It's is amyloid, strategy. – are

of ADUHELM – that not can drugs, are it drugs, also date, all I about evidence you're to you interpretation looking you, forget the tell but efficacy. anti-tau drug great, same And have at that's Genotek efficacy, Lilly there knowledge, Biogen quite works. my looking we whether is I'll to any whether think that target it it or of people Now, subpar. therapy honestly, amyloid had at the drug, no And my the which, is that you're tell three is data

community the to it's anti-amyloid So I other are is are, turning they're approaches to anti-tau time and sit, going be think the going where old strategies think the and and we where fashion the – approaches. be, know to where I to

mentions, more is I important. getting might Neuroinflammation you are viewed say. We as guess,

have preclinical data. We great

great data. up Phase to Phase to great have data. X It's now us X We produce

to when that want you become understand on will XPro. XX, you you all be So

Daniel Carlson

That's it Appreciate me. much. for Guys, very color. that you thank

Operator

further back questions for no I'd this to floor to RJ are time. over There at closing like any comments. turn the

RJ Tesi

thank joining. all you for So

I think INKmune new solid increased interest we presented and a in little our tumors. bit of here information with

management can will us confidence to enthusiastic off. the we we have have and the give trial I XPro that can so clinical you And we sign about think hear us, you that, up company, and it's we disease. enrollments at are. answers for as in the to understand program Alzheimer's our With these you get the drive we programs

Operator

conference. today’s concludes This

Thank your may disconnect time. this participation. at your for You lines you

INmune Bio (INMB) 8 May 222022 Q1 Earnings call transcript